Identifying Quality Dividend Stocks When Yields Are Low
Success in today's dividend investing landscape requires abandoning the outdated practice of simply chasing the highest yields.
Charles Rotblut, Doug Gerlach
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Success in today's dividend investing landscape requires abandoning the outdated practice of simply chasing the highest yields.
Charles Rotblut, Doug Gerlach
Jack Gilleland
Eunice Kim
Jenna Brashear
Grace Malone
| Share Statistics | ABT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $182,901.5 | $337.2 | 98% |
|
| Shares Out (Mil) | 1,743.0 | 41.9 | 97% |
|
| Institutional Ownership | 99.4% | 77.8% | 88% |
|
| Float (Mil) | 1,719.7 | 34.7 | 95% |
|
| Beta | 0.61 | 0.85 | 35% |
|
| Avg Daily Volume (000s) | 11,077 | 278 | 97% |
|
| Price Change (52-week) |
(17.8%) | 58.7% | 32% |
|
| Growth | ABT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 5.1% | 11.8% | 37% |
|
| Net Income (5yr) | 7.7% | (5.8%) | 51% |
|
| EPS (5yr) | 8.2% | 11.4% | 43 |
|
| Dividends (5yr) | 9.4% | 0.0% | 92% |
|
| Cash Flow (5yr) | (20.9%) | (16.3%) | 31% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 22 | 25 | 25 | |
| Current EPS | $1.419 | $5.517 | $6.063 | |
| Month Ago EPS | $1.421 | $5.482 | $6.058 | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | $1.419 | $5.483 | $6.064 | |
| Year/Year Chg | 167.7% | 48.3% | 80.6% | |
| Financials | ABT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $46,585 | $152 | 96% |
|
| Net Income (TTM) (Mil) | $5,425 | ($10) | 97% |
|
| EPS (TTM) | $3.102 | ($0.500) | 79% |
|
| Operating Cash Flow (TTM) (Mil) | $9,905 | ($2) | 98% |
|
| Net Cash Flow (TTM) (Mil) | ($1,847) | $1 | 2% |
|
| Long-Term Debt (Q1) (Mil) | $29,703 | $22 | 97% |
|
| Enterprise Value (Q1) (Mil) | $214,650 | $304 | 99% |
|
| Valuation | ABT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.58 | 2.80 | 70% |
|
| P/E | 34.2 | 31.1 | 73% |
|
| Dividend Yield | 2.4% | 0.0% | 79% |
|
| PEG (5yr hist) | 4.1 | 1.9 | 84% |
|
| Ratios | ABT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 56.8% | 59.1% | 69% |
|
| Net Margin | 11.6% | (7.3%) | 67% |
|
| ROA | 5.6% | (13.7%) | 75% |
|
| ROE | 10.7% | (15.8%) | 60% |
|
| Liabilities to Assets | 52.6% | 44.7% | 45% |
|
| F-Score | 5 | 4 | 51% |
|
Abbott Laboratories did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors